SGLT2 Inhibitor Plus MRA Further Reduces Albuminuria
Study findings indicate synergistic effects of SGLT2 inhibitors and MRAs on albuminuria.
Study findings indicate synergistic effects of SGLT2 inhibitors and MRAs on albuminuria.
The prevalence of diabetic kidney disease is higher among US veterans than the general population, investigators noted.
Patients with stage 4 diabetic kidney disease are understudied and lack treatment options.
Previous GLP-1RA trials have mostly excluded patients with advanced diabetic kidney disease.
Histologic lesions in the kidney may reflect systemic processes that lead to cardiovascular events, according to investigators.
The ratio is a clinically meaningful indicator that is easily obtained from blood test results, according to investigators.
Early identification of patients at high risk of hyperuricemia using the triglyceride-glucose index may permit prompt intervention.
Compared with annual screening for urinary albumin, personalized screening can reduce time spent with undetected albuminuria, testing frequency
Treatment with an SGLT2 inhibitor may help patients with CKD or type 2 diabetes better preserve their kidney function.
Finerenone, a mineralocorticoid receptor antagonist, may exert anti-inflammatory and anti-fibrotic effects, according to investigators.